HomePRLD • NASDAQ
Prelude Therapeutics Inc
add
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 34.61M | 0.77% |
Net income | -32.09M | -2.08% |
Net profit margin | — | — |
Earnings per share | -0.42 | 0.00% |
EBITDA | -34.17M | -0.75% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 99.07M | -50.94% |
Total assets | 141.26M | -42.83% |
Total liabilities | 38.08M | 4.70% |
Total equity | 103.18M | — |
Shares outstanding | 56.46M | — |
Price to book | 0.51 | — |
Return on assets | -54.62% | — |
Return on capital | -63.95% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -32.09M | -2.08% |
Cash from operations | -34.23M | -7.68% |
Cash from investing | 62.19M | 99.18% |
Cash from financing | -160.00K | -1,042.86% |
Net change in cash | 27.80M | 4,859.42% |
Free cash flow | -24.26M | -13.06% |
Previous close
$0.94
Year range
$0.61 - $6.80
Market cap
53.07M USD
Avg Volume
134.83K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Founded
2016
Headquarters
Website
Employees
131
